Suspension of trading

Spexis AG Share Price Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Delayed Swiss Exchange 10:06:37 19/03/2025 pm IST 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 8L
+0.11%-3.98%+13.89%-11.26% 6.63TCr
+2.43%+3.97%+39.07%+205.58% 5.26TCr
+0.51%+37.90%+37.90%+37.90% 4.33TCr
-1.32%-7.38%-57.63%-57.10% 3.86TCr
+1.46%-3.97%+53.17%-27.51% 2.96TCr
+0.78%+0.03%+65.07%+81.90% 2.33TCr
-1.81%-9.71%+64.46%-54.90% 2.26TCr
-1.21%+1.12%+1.98%+170.93% 2.02TCr
+0.07%-0.91%+62.04%+123.87% 1.63TCr
Average +0.45%-2.89%+19.11%+37.02% 3.48TCr
Weighted average by Cap. +0.54%-2.60%+25.54%+47.38%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B